p38丝裂原活化蛋白激酶：心力衰竭治疗的未来靶点？ - Suppr

Suppr

超能文献

p38 mitogen-activated protein kinase: a future target for heart failure therapy?

作者信息

Kerkela Risto, Force Thomas

出版信息

J Am Coll Cardiol. 2006 Aug 1;48(3):556-8. doi: 10.1016/j.jacc.2006.05.005. Epub 2006 Jul 12.

DOI:10.1016/j.jacc.2006.05.005

PMID:16875983

Abstract

摘要

相似文献

p38 mitogen-activated protein kinase: a future target for heart failure therapy?

J Am Coll Cardiol. 2006 Aug 1;48(3):556-8. doi: 10.1016/j.jacc.2006.05.005. Epub 2006 Jul 12.

Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.

Pharmacol Ther. 2007 Nov;116(2):192-206. doi: 10.1016/j.pharmthera.2007.06.013. Epub 2007 Jul 24.

SCIO-469 Scios Inc.

Curr Opin Investig Drugs. 2004 Nov;5(11):1205-12.

Inhibitors of unactivated p38 MAP kinase.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6102-6. doi: 10.1016/j.bmcl.2006.08.101. Epub 2006 Sep 12.

Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.

J Cardiovasc Pharmacol. 2007 Jun;49(6):362-8. doi: 10.1097/FJC.0b013e318046f34a.

New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

Circulation. 2012 Jul 17;126(3):357-68. doi: 10.1161/CIRCULATIONAHA.111.071886.

Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways.

J Allergy Clin Immunol. 2008 Apr;121(4):893-902.e2. doi: 10.1016/j.jaci.2008.02.004.

Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo.

J Biomed Mater Res A. 2009 Apr;89(1):117-23. doi: 10.1002/jbm.a.31957.

Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury.

Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E183-9. doi: 10.1152/ajpendo.00571.2007. Epub 2007 Nov 14.

Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors.

Chem Biol Drug Des. 2007 Jan;69(1):23-30. doi: 10.1111/j.1747-0285.2007.00474.x.

引用本文的文献

Redox Regulation of Cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) Controls p38-MAPK (Mitogen-Activated Protein Kinase) and Orchestrates Cardiac Remodeling to Hypertension.

Hypertension. 2020 Oct;76(4):1208-1218. doi: 10.1161/HYPERTENSIONAHA.119.14556. Epub 2020 Sep 9.

Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.

Cancer Med. 2020 Apr;9(8):2611-2620. doi: 10.1002/cam4.2922. Epub 2020 Feb 14.

Improved heart failure by Rhein lysinate is associated with p38MAPK pathway.

Exp Ther Med. 2018 Sep;16(3):2046-2051. doi: 10.3892/etm.2018.6423. Epub 2018 Jul 9.

Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins.

Cardiovasc Res. 2018 May 1;114(6):846-857. doi: 10.1093/cvr/cvy040.

Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.

Cardiovasc Toxicol. 2017 Oct;17(4):487-493. doi: 10.1007/s12012-017-9425-z.

Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.

Ther Clin Risk Manag. 2016 Jun 3;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016.

Effects of Wenyangzhenshuai Granule on ERK1/2 and ERK5 activity in the myocardial tissue in a rabbit model of adriamycin-induced chronic heart failure.

Int J Clin Exp Med. 2015 Nov 15;8(11):20732-41. eCollection 2015.

Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial.

Pharmacogenomics J. 2017 Jan;17(1):76-83. doi: 10.1038/tpj.2015.84. Epub 2015 Dec 8.

The case for inhibiting p38 mitogen-activated protein kinase in heart failure.

Front Pharmacol. 2015 May 12;6:102. doi: 10.3389/fphar.2015.00102. eCollection 2015.

Heart failure: novel therapeutic approaches.

J Postgrad Med. 2015 Apr-Jun;61(2):101-8. doi: 10.4103/0022-3859.153104.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

p38 mitogen-activated protein kinase: a future target for heart failure therapy?

作者信息

Kerkela Risto, Force Thomas

出版信息

J Am Coll Cardiol. 2006 Aug 1;48(3):556-8. doi: 10.1016/j.jacc.2006.05.005. Epub 2006 Jul 12.

DOI:10.1016/j.jacc.2006.05.005

PMID:16875983

Abstract

摘要

相似文献

p38 mitogen-activated protein kinase: a future target for heart failure therapy?

J Am Coll Cardiol. 2006 Aug 1;48(3):556-8. doi: 10.1016/j.jacc.2006.05.005. Epub 2006 Jul 12.

Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.

Pharmacol Ther. 2007 Nov;116(2):192-206. doi: 10.1016/j.pharmthera.2007.06.013. Epub 2007 Jul 24.

SCIO-469 Scios Inc.

Curr Opin Investig Drugs. 2004 Nov;5(11):1205-12.

Inhibitors of unactivated p38 MAP kinase.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6102-6. doi: 10.1016/j.bmcl.2006.08.101. Epub 2006 Sep 12.

Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.

J Cardiovasc Pharmacol. 2007 Jun;49(6):362-8. doi: 10.1097/FJC.0b013e318046f34a.

New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

Circulation. 2012 Jul 17;126(3):357-68. doi: 10.1161/CIRCULATIONAHA.111.071886.

Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways.

J Allergy Clin Immunol. 2008 Apr;121(4):893-902.e2. doi: 10.1016/j.jaci.2008.02.004.

Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo.

J Biomed Mater Res A. 2009 Apr;89(1):117-23. doi: 10.1002/jbm.a.31957.

Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury.

Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E183-9. doi: 10.1152/ajpendo.00571.2007. Epub 2007 Nov 14.

Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors.

Chem Biol Drug Des. 2007 Jan;69(1):23-30. doi: 10.1111/j.1747-0285.2007.00474.x.

引用本文的文献

Redox Regulation of Cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) Controls p38-MAPK (Mitogen-Activated Protein Kinase) and Orchestrates Cardiac Remodeling to Hypertension.

Hypertension. 2020 Oct;76(4):1208-1218. doi: 10.1161/HYPERTENSIONAHA.119.14556. Epub 2020 Sep 9.

Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.

Cancer Med. 2020 Apr;9(8):2611-2620. doi: 10.1002/cam4.2922. Epub 2020 Feb 14.

Improved heart failure by Rhein lysinate is associated with p38MAPK pathway.

Exp Ther Med. 2018 Sep;16(3):2046-2051. doi: 10.3892/etm.2018.6423. Epub 2018 Jul 9.

Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins.

Cardiovasc Res. 2018 May 1;114(6):846-857. doi: 10.1093/cvr/cvy040.

Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.

Cardiovasc Toxicol. 2017 Oct;17(4):487-493. doi: 10.1007/s12012-017-9425-z.

Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.

Ther Clin Risk Manag. 2016 Jun 3;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016.

Effects of Wenyangzhenshuai Granule on ERK1/2 and ERK5 activity in the myocardial tissue in a rabbit model of adriamycin-induced chronic heart failure.

Int J Clin Exp Med. 2015 Nov 15;8(11):20732-41. eCollection 2015.

Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial.

Pharmacogenomics J. 2017 Jan;17(1):76-83. doi: 10.1038/tpj.2015.84. Epub 2015 Dec 8.

The case for inhibiting p38 mitogen-activated protein kinase in heart failure.

Front Pharmacol. 2015 May 12;6:102. doi: 10.3389/fphar.2015.00102. eCollection 2015.

Heart failure: novel therapeutic approaches.

J Postgrad Med. 2015 Apr-Jun;61(2):101-8. doi: 10.4103/0022-3859.153104.